[미국특허]
Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/435
A61K-031/439
A61K-031/53
A61K-047/30
C07D-319/04
A61K-009/00
A61K-047/34
출원번호
US-0552083
(2012-07-18)
등록번호
US-8715710
(2014-05-06)
발명자
/ 주소
Ng, Steven Y.
Shen, Hui Rong
Heller, Jorge
출원인 / 주소
Heron Therapeutics, Inc.
대리인 / 주소
Evans, Susan T.
인용정보
피인용 횟수 :
1인용 특허 :
38
초록▼
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the a
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
대표청구항▼
1. A semi-solid pharmaceutical composition comprising a polyorthoester, 10-50 weight percent polyethylene glycol monomethyl ether having a molecular weight in a range of 200 to 4,000, and about 1-5 weight percent granisetron, the polyorthoester comprising subunits selected from: wherex is an integer
1. A semi-solid pharmaceutical composition comprising a polyorthoester, 10-50 weight percent polyethylene glycol monomethyl ether having a molecular weight in a range of 200 to 4,000, and about 1-5 weight percent granisetron, the polyorthoester comprising subunits selected from: wherex is an integer from 1-4,the total amount of p is an integer from 1-20,s is an integer from 1-4,the mole percentage of α-hydroxyacid containing subunits in the polyorthoester is from about 0.1 to about 25 mole percent, and the polyorthoester has a molecular weight in a range of 1000 to 10,000. 2. A semi-solid pharmaceutical composition comprising a polyorthoester, 10-50 weight percent polyethylene glycol monomethyl ether having a molecular weight in a range of 200 to 4,000, and 1-5 weight percent granisetron, where the polyorthoester comprises alternating residues of 3,9 -diethyl-3,9-2,4,8,10-tetraoxaspiro[5.5] undecane-3,9-diyl: and a diol-ate residue of triethylene glycol or of triethylene glycol diglycolide prepared by reacting triethylene glycol with from 0.5 to 10 molar equivalents of glycolide at 100-200° C. for about 12 hours to 48 hours, where the mole percentage of glycolide-containing subunits in the polyorthoester is from about 0.1 to about 25 mole percent, and the polyorthoester has a molecular weight of 1000 to 10,000. 3. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the polyethylene glycol monomethyl ether has a molecular weight of about 550. 4. The semi-solid pharmaceutical composition of claim 1 or claim 2, comprising from 2-3 weight percent granisetron. 5. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the granisetron is in the form of a free base. 6. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the granisetron is in the form of an acid addition salt. 7. The semi-solid pharmaceutical composition of claim 1 or claim 2, comprising 78.4 weight percent polyorthoester, 19.6 weight percent polyethylene glycol monomethyl ether and 2 weight percent granisetron. 8. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the polyorthoester has a molecular weight of about 6,500. 9. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the composition is stable upon irradiation. 10. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the composition is stable upon sterilization. 11. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the granisetron is in the form of a solid having a particle size of less than 100 microns. 12. The semi-solid pharmaceutical composition of claim 1 or claim 2, wherein the composition is capable of being dispensed from a 16-25 gauge needle. 13. The semi-solid pharmaceutical composition of claim 1 or claim 2, effective to release the granisetron in a sustained and controlled manner after administration.
Chandrashekar Bhagya L. ; Zhou Mingxing ; Jarr Eileen M. ; Dunn Richard L., Controlled release liquid delivery compositions with low initial drug burst.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Heller Jorge (Woodside CA) Ng Steve Y. W. (San Francisco CA) Penhale Donald W. H. (Menlo Park CA), Polymers containing carboxy-ortho ester and ortho ester linkages.
Heller Jorge (Palo Alto CA) Helwing Robert F. (Sunnyvale CA) Penhale Donald W. (Cupertino CA), Polymers of di- (and higher functionality) ketene acetals and polyols.
Cohen Edward M. (Beaumont PA FRX) Grim Wayne M. (Doylestown PA) Harwood Richard J. (Philadelphia PA) Mehta Gunvant N. (Lansdale PA), Solid state ophthalmic medication.
Berger Jacob (Los Altos Hills) Clark Robin D. (Palo Alto) Eglen Richard M. (Mountain View) Smith William L. (Sunnyvale) Weinhardt Klaus K. (San Francisco CA), Tricyclic 5-HT3receptor antagonists.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.